Arcutis launches Zoryve for atopic dermatitis in USA

California’s Arcutis Biotherapeutics (Nasdaq: ARQT), a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years.

Zoryve is a once-daily, steroid-free cream that is shown to provide rapid disease clearance and significant reduction in itch, and was developed to provide long-term disease control.

Todd Edwards, chief commercial officer at Arcutis, said: “Atopic dermatitis is a complex disease that affects tens of millions of adults and children in the USA. While topical therapies are often prescribed to treat this chronic disease, they come with limitations on duration of use or side effects that require careful management. Zoryve is a once-daily cream developed with the atopic dermatitis patient in mind, that can effectively and safely be used to relieve symptoms anywhere on the body.